Skip to main content
OpenTrials
Completed

NCT Number: NCT03790202

VistaCare® in the Treatment of Wounds of the Lower Extremity

Assessment of the safety and performance of the VistaCare® medical device in current medical practice in the treatment of acute and chronic lower limb wounds.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Wound Heal Wounds and Injuries

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Henri Mondor, Créteil, France

Loading trial locations.

About this study

The study is an open-label, prospective, multicenter, post-CE mark (European Conformity assessment indicating marketing approval in Europe) study to assess the safety and performance of the VistaCare® device in the treatment of wounds. The duration of patient follow-up is up to 30 days, with intermediate visits at 3, 7, 15 and 30 days following initiation of treatment with the device.

Up to 30 patients will be recruited in the trial. Assessments will include clinical status, wound status, standardized photography, TcPO2 (trans-cutaneous oxygen pressure assessment) in a study sub-population, visual analogy scales to assess pain and comfort and adverse events monitoring.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • male or female consenting and able patients aged 18 or more affiliated to social security
  • presenting with acute or chronic traumatic or surgical lower limb wounds (excluding tumoral excision)
  • presenting with no intercurrent pathology which in the opinion of the investigator may interfere with the capacity for wound healing
  • patients whose wound is compatible in terms of location with VistaCare treatment
  • patient whose wound has a minimal surface of 10 cm2
  • patient whose wound does not need surgical Peterson after inclusion (if needed should be performed prior to inclusion)

Exclusion criteria

  • Female patients pregnant, lactating, or of childbearing age and not using adequate contraception (pregnancy test mandatory)
  • patients incapable of making an informed decision about participation
  • patients presenting a condition that interferes with adequate wound healing capacity (uncontrolled diabetes, heavy smokers, auto-immune disease)
  • concurrent treatment or treatment within one month prior to inclusion with local or systemic corticosteroids, immunosuppresseurs, chemotherapy or radiotherapy
  • wound location incompatible with VistaCare
  • general infection signs at the time of inclusion (fever, lymphangitis, pus ...)
  • patients presenting with important uncontrolled hemorrhage at the time of inclusion
  • patients previously recruited into this trial or any other trial within 1 month, or currently in the exclusion timeframe of another trial
  • patients with a wound surface less than 10 cm2
  • patient with a would previously treated with hyperbaric chamber
  • legally incapacitated, under guardianship or psychiatric patients
  • emergency condition prohibiting adequate patient consent prior to inclusion

Treatment and study plan

VistaCare®

Device

Controlled atmosphere wound healing device

Primary outcomes

  1. Assessment of the global Safety of use of the VistaCare® medical device in standard medical practice

    Time frame: up to 30 days

    Assessment of the global safety of VistaCare® in current medical practice in patients with acute or chronic lower limb wounds through monitoring of concurrent averse events throughout the study duration. This will be assessed through the frequency of occurrence of device-related events, throughout the patient's participation in the trial

  2. Assessment of the global Performance of the VistaCare® device in standard medical practice

    Time frame: up to 30 days

    Assessment of the global performance of the VistaCare® medical device as compared to its labeled performance in the approved indication (wound healing). This will be assessed through a global clinical assessment by the investigator of the wound improvement condition throughout the study visits, measured in 3 grades ranging from Aggravation (worst assessment), through Static (no improvement) to Improved (best assessment), taking into consideration the wound healing stage and general clinical condition per investigator's assessment.

Secondary outcomes

  1. Assessment of time under VistaCare treatment till secondary treatment decision

    Time frame: up to 15 days

    Assessment of the time in days till decision to wound coverage, graft, wound dressing, or no further treatment needed and patient discharge. Duration in days from VistaCare treatment initiation to decision-making will be tabulated for each patient.

  2. Wound surface calorimetric assessment of wound status

    Time frame: 30 days

    Description of wound clinical status evolution through photography, wound measurement in mm2 and visual assessment of wound status. This measure is based on the surface in mm2 of the wound components on a standard photography, each wound potentially comprising 3 wound stages surfaces : necrotic (worst), granulation and epithelization (most favorable wound healing stage). Those stages are measured on each visit on a standardized photography of the wound and the wound stage evolution in time is assessed for each patient by an external reviewer. Wound staging for each patient will be analyzed in time throughout patient's participation and presented as graphs.

  3. Safety assessment of the VistaCare® treatment through monitoring of the frequency of adverse events

    Time frame: throughout 30 days

    Safety assessment of the VistaCare® treatment through adverse events monitoring, with frequency of patients presenting with any adverse event and frequency of each adverse event type, namely non-serious unrelated or device-related event (respectively AE, ADE), serious unrelated event (SAE), serious device-related event (SADE), unanticipated device-related event (UADE), or device deficiency. Tabulation of frequencies in percentages of patient occurrence and number of events per patient will be provided.

  4. TcPO2 assessment

    Time frame: up to 30 days

    In a sub-group of up to 10 patients, measure of the trans-cutaneous oxygen pressure (TcPO2) around the wound to assess status and potential correlation with wound status. This measure is expressed in mmHG and the correlation between this measure and the wound healing stage will be statistically assessed to indicate if wound healing may be correlated to the oxygen pressure measure.

  5. Quality of Life assessments

    Time frame: throughout 30 days

    Patient visual analogy scale (VAS) assessments of pain and comfort. Those scales are each graduated from 0 (none) to 10 (maximum pain or discomfort). The evolution in times of such scores will be statistically assessed for each patient.

  6. Duration of hospitalization

    Time frame: throughout 30 days

    Assessment of the total duration of patient hospitalization in days.

Sponsors and collaborators

Lead sponsor

DTAMedical SAS

Industry

Registry information

Official study title

Open Label Assessment of VistaCare® Treatment in Current Medical Practice in Patients With Acute and Chronic Leg Wounds.

Important dates

Study start
2019
Primary completion
2020
Study completion
2021
First posted
Dec 31, 2018
Registry last updated
Feb 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.